Ipamorelin vs CJC-1295 No DAC: Comparing Growth Hormone Secretagogue Research

Research Notice: All peptides sold by The Peptide Store are intended for laboratory research purposes only. They are not for human consumption, not approved by the FDA, and not intended to diagnose, treat, cure, or prevent any disease.

Research summary: Ipamorelin and CJC-1295 (no DAC) are growth hormone secretagogues that work through distinct pathways. Ipamorelin is a selective GHS-R (ghrelin receptor) agonist that stimulates GH release with minimal effect on cortisol, prolactin, or ACTH. CJC-1295 without DAC — also called Mod GRF 1-29 — is a modified GHRH analogue acting on the GHRH receptor. The two are studied together for GH-axis research designs. Sold for laboratory research use only.

Ipamorelin and CJC-1295 (no DAC) are growth hormone secretagogues that operate through distinct receptor pathways. Understanding their different mechanisms is essential for designing rigorous research protocols involving the GH axis.

Ipamorelin: Selective GHS-R Agonist

Ipamorelin is a synthetic pentapeptide that acts as a selective GH secretagogue receptor (GHS-R) agonist — specifically at the ghrelin receptor. Studies published in the European Journal of Endocrinology have examined its pharmacokinetics and GH release profiles. Its selectivity — stimulating GH with minimal effect on cortisol, prolactin, or ACTH — makes it a useful tool for isolating GH-related effects in research designs.

CJC-1295 No DAC: GHRH Analogue

CJC-1295 without DAC (also called Mod GRF 1-29) is a modified form of Growth Hormone Releasing Hormone (GHRH) that operates through the GHRH receptor on pituitary somatotrophs — a fundamentally different receptor than Ipamorelin’s target. Its modifications improve stability over endogenous GHRH while maintaining a shorter half-life than the DAC version.

Synergistic Research Design

Because Ipamorelin and CJC-1295 no DAC operate through complementary receptor pathways, research has demonstrated synergistic GH secretion when both are used simultaneously. This dual-receptor approach is a common research design specifically because of this documented synergy. The CJC-1295 No DAC and Ipamorelin are both available individually.